8-K: Novartis to Acquire Avidity Biosciences for $12B

Novartis AG will acquire Avidity Biosciences for $72.00 per share in cash, valuing the company at approximately $12.0 billion, while Avidity's early-stage cardiology programs will spin off into a new publicly traded entity, SpinCo.

Summary

• Novartis AG will acquire Avidity Biosciences, Inc. for $72.00 per share in cash, representing a total equity value of approximately $12.0 billion on a fully diluted basis.
• The acquisition price represents a premium of approximately 46% over Avidity's closing share price of $49.15 on October 24, 2025, and approximately 62% over Avidity's October 24 closing 30-day volume weighted average price of $44.42.
• Prior to the acquisition, Avidity will transfer its early-stage precision cardiology programs and certain collaboration agreements into a newly formed, wholly owned subsidiary, Bryce Therapeutics, Inc. (SpinCo).
• SpinCo is expected to become a separate, independent publicly traded company and will be capitalized with $270 million in cash.
• Avidity stockholders will receive a distribution of one share of SpinCo common stock for every ten shares of Avidity common stock they hold, or a pro rata cash distribution if certain SpinCo assets or SpinCo itself is sold to a third party.
• The merger and spin-off transactions are expected to close in the first half of 2026, subject to regulatory approvals, Avidity stockholder approval, and completion of the SpinCo separation.

Sentiment

Score: 9

Explanation: The acquisition by Novartis at a significant premium, coupled with the spin-off of a well-capitalized new entity for early-stage cardiology programs, represents a highly favorable outcome for Avidity shareholders and validates its AOC platform technology.

Positives

• Avidity shareholders will receive a significant cash premium of $72.00 per share, representing a 46% premium over the previous day's closing price and 62% over the 30-day volume weighted average price.
• Shareholders will also receive shares in the newly formed SpinCo, allowing them to retain exposure to Avidity's early-stage precision cardiology programs and potential future growth in that sector.
• SpinCo will be well-capitalized with $270 million in cash, providing a strong financial foundation for its independent operations and development of its pipeline.
• Novartis gains access to Avidity's differentiated RNA-targeting delivery platform and its late-stage neuroscience pipeline, including programs for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD).
• The transaction is expected to maximize value for Avidity investors and support the global expansion of the neuroscience pipeline under Novartis.

Negatives

• The spin-off and merger are expected to be taxable events for Avidity's stockholders.
• The transaction is subject to various closing conditions, including regulatory approvals and stockholder adoption, which could delay or prevent its completion.
• There is a risk of disruption to Avidity's businesses, including relationships with employees, business partners, or governmental entities, due to the announcement and pendency of the transactions.
• The transactions may incur higher-than-anticipated costs.
• Stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• The transactions will divert management's attention from ongoing business operations and opportunities.

Risks

• The timing of the satisfaction of customary closing conditions, including regulatory approvals and the approval of Avidity's stockholders, on acceptable terms or at all.
• Risks and costs related to the implementation of the separation of SpinCo, including the ability to complete the separation in the anticipated timeframe, or at all, and any changes to the configuration of the businesses included in the separation if implemented.
• The sale of certain of SpinCo's assets pursuant to a third-party right of first negotiation.
• The risk that competing offers or acquisition proposals will be made.
• The effects of disruption from the Transactions and the impact of the announcement and pendency of the Transactions on Novartis and/or Avidity's businesses, including their relationships with employees, business partners or governmental entities.
• The risk that the Transactions may be more expensive to complete than anticipated.
• The risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification and liability.
• A diversion of management's attention from ongoing business operations and opportunities as a result of the Transactions or otherwise.
• The uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.
• There can be no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.
• There can be no guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.

Future Outlook

Novartis will acquire Avidity's neuroscience pipeline and its differentiated RNA-targeting delivery platform, including three late-stage clinical development programs for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). SpinCo will focus on Avidity's early-stage precision cardiology programs, including AOC 1086 and AOC 1072, which target rare genetic cardiomyopathies, and will continue to develop Avidity's proprietary platform for cardiology applications. The transactions are expected to close in the first half of 2026.

Management Comments

• Sarah Boyce, President and Chief Executive Officer of Avidity, stated: "Avidity has expanded the possibilities of what RNA therapeutics can deliver to patients by advancing innovative science and creating an organization with a strong commitment to providing access to our potential medicines. We are confident that this transaction with Novartis maximizes value for our investors and will support the global expansion of our neuroscience pipeline."
• Kathleen Gallagher, currently Chief Program Officer at Avidity and incoming Chief Executive Officer of SpinCo, commented: "We have already seen the tremendous impact targeted delivery of RNA therapeutics to muscle can have for people living with rare diseases based on the impressive advancements Avidity has made with its neuroscience programs. Avidity's precision cardiology pipeline is poised to progress rapidly, and I am excited to lead the team that will build on our groundbreaking AOC platform with the potential to address high unmet need in cardiovascular diseases."

Industry Context

This acquisition underscores the growing strategic importance of RNA therapeutics and targeted delivery platforms in the biopharmaceutical industry. Novartis's move to acquire Avidity's advanced RNA-targeting delivery platform and late-stage neuroscience pipeline signals a strong commitment to expanding its portfolio in rare diseases and genetic medicines. The concurrent spin-off of Avidity's early-stage precision cardiology programs into a new, well-capitalized public company, SpinCo, reflects a trend of large pharmaceutical companies streamlining acquisitions to focus on core strategic areas while allowing promising, but non-core, assets to pursue independent development and unlock value. This strategy enables specialized focus and caters to different investor appetites for early-stage versus late-stage assets, potentially accelerating the development of novel therapies across multiple therapeutic areas.

Comparison to Industry Standards

• The acquisition premium of 46% over Avidity's closing share price and 62% over its 30-day volume weighted average price is substantial, indicating a strong valuation for Avidity's innovative Antibody Oligonucleotide Conjugate (AOC) platform and its late-stage neuroscience pipeline. Such premiums are often observed in strategic acquisitions of biotech companies with differentiated technologies and promising clinical assets, reflecting the high value placed on innovation in the biopharmaceutical sector.
• The capitalization of SpinCo with $270 million in cash provides a robust financial foundation for a newly independent, early-stage biotech company. This level of initial funding is generally considered strong for a spin-off, enabling it to advance its precision cardiology programs without immediate capital constraints, a common challenge for emerging biotechs.
• The deal structure, involving a carve-out and spin-off of early-stage assets (precision cardiology) before the acquisition of the core business (neuroscience pipeline and platform), is a sophisticated strategy employed by large pharmaceutical companies. This approach allows the acquirer, Novartis, to focus on integrating the more advanced and strategically aligned assets, while the spun-off entity can attract investors interested in higher-risk, higher-reward early-stage development. This mirrors strategies seen in other major pharma deals where non-core assets are divested to optimize the acquired portfolio.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes a risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• **Shareholders**: Will receive a substantial cash premium for their Avidity shares and shares/cash in SpinCo, providing immediate financial benefit and continued investment opportunity in early-stage cardiology.
• **Employees**: Employees associated with the neuroscience pipeline and AOC platform will transition to Novartis, while those in early-stage precision cardiology will join SpinCo, led by a new management team. Employment terms for Transferred Employees are outlined for a period post-distribution.
• **Collaboration Partners**: Existing collaborations with Bristol Myers Squibb and Eli Lilly and Company will continue with SpinCo, focusing on cardiology programs. A right of first negotiation with an existing collaboration partner for certain Avidity assets is triggered.
• **Patients/Industry**: The acquisition by Novartis could accelerate the development and global reach of Avidity's neuroscience RNA therapeutics, potentially benefiting patients with rare muscle diseases. SpinCo's independent focus on precision cardiology aims to address high unmet needs in cardiovascular diseases.

Next Steps

• Avidity will prepare and file a preliminary proxy statement within 30 days after October 25, 2025, for the special meeting of stockholders.
• Avidity will use reasonable best efforts to submit or file the Spin-Off Registration Statement within 60 days after October 25, 2025, and no later than 90 days after October 25, 2025.
• Avidity will duly call, give notice of, convene, and hold a special meeting of its stockholders to obtain the Requisite Company Vote for the adoption of the Merger Agreement and Separation and Distribution Agreement.
• Avidity will cooperate with Parent to cause the delisting of Avidity Common Stock from Nasdaq and deregistration under the Exchange Act as promptly as practicable after the Effective Time.
• SpinCo will prepare and file with Nasdaq a listing application for SpinCo Common Stock and use reasonable best efforts to have it listed prior to the Distribution Effective Time.
• Avidity, SpinCo, and Parent will use reasonable best efforts to agree upon a lab recommissioning plan for Science Center Drive and a data and materials separation plan within 20 Business Days after October 25, 2025.
• The Company, together with the RemainCo Group, will complete the transfer of all tangible embodiments of the SpinCo Assets to SpinCo and the SpinCo Group within nine months following the Distribution Effective Time.
• Novartis and Avidity will continue to operate as separate and independent companies until the closing of the transactions.

Key Dates

Recommendation

The acquisition by Novartis at a substantial premium of 46% over the previous day's closing price and 62% over the 30-day VWAP offers immediate and significant value to Avidity shareholders. Furthermore, the spin-off of SpinCo, capitalized with $270 million and focused on early-stage precision cardiology, provides shareholders with continued exposure to a promising pipeline in a distinct therapeutic area. This dual benefit of a high-value cash exit for the main business and retained upside potential in a new entity makes this a highly attractive transaction for investors.

Keywords

Avidity Biosciences, Novartis, Acquisition, Merger, Spin-off, RNA therapeutics, Antibody Oligonucleotide Conjugates, AOCs, Neuroscience pipeline, Precision cardiology, Duchenne muscular dystrophy, DMD, Myotonic dystrophy type 1, DM1, Facioscapulohumeral muscular dystrophy, FSHD, Rare genetic cardiomyopathies, Biopharmaceutical, Biotech, Pharmaceutical